Aller au contenu principal
2017 article

The clinical significance of CYP2C19 genotype detection for antiplatelet therapy of cardiovascular and cerebrovascular diseases in the elderly

0Citations signalées, ce qui n’est pas une note de qualité
2Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Objectives To investigate the clinical significance of CYP2C19 genotype detection for antiplatelet therapy of elder cardiovascular and cerebrovascular diseases(CCVD). Methods We enrolled all elderly patients with either cardiovascular or cerebrovascular disorders who received clopidogrel as mono drug or in combination with another antiplatelet drug aspirin as secondary prevention for more than 12 months in our hospital from January to August 2015.Somatotypes of CYP2C19 genotypes of all participants were assessed to analyze the relapse of cardiac-cerebral vascular diseases in these patients. Results A total of 250 patients were enrolled, including 179 male and 71 female, with average age of (85.2±7.9)years.Among these patients, there were 97(38.8%)cases with EM CYP2C19 genotypes, 110 cases(44.0%)with IM CYP2C19 genotypes, 43 cases(17.2%)with PM CYP2C19 genotypes.When treated with clopidogrel for antiplatelet in secondary prevention process, the rate of the relapse in cardiovascular event was 34.9% and higher in PM CYP2C19 genotype than in EM and IM CYP2C19 genotype(19.6% and 15.5%, respectively)(χ2=7.251, P=0.027). This phenomenon was similar to patients who received stent implantation(χ2=6.393, P=0.041). However, no statistically significant difference was observed in the recurrence rate of cerebral vascular disease between three different genotypes(EM 29.9%, IM 20.0%, PM 27.9%, χ2=2.880, P=0.237). Conclusions Our results highlight that CYP2C19 genotype might be a potential guidance for secondary prevention of cardiovascular and cerebrovascular disorders among elderly patients.Clopidogrel may be less effective in patients with SM CYP2C19 genotype than those with EM or PM CYP2C19 genotype for secondary prevention of cardiovascular disease. Key words: Cardiovascular diseases; Blood platelets; Polymorphism, single nucleotide

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

La source scientifique ouverte est momentanément indisponible.

Où se fait cette recherche

  • Guangzhou Medical University pays non établi dans la notice
    Université ou école supérieure
  • Guangzhou First People's Hospital pays non établi dans la notice
    Établissement de santé
  • Zengcheng District People′s Hospital of Guangzhou Department of Neurology pays non établi dans la notice
    Établissement de santé
  • Public Health College pays non établi dans la notice
    Université ou école supérieure
  • Guangzhou First People′s Hospital pays non établi dans la notice
    Établissement de santé

Guangzhou Medical University, Guangzhou First People's Hospital et Department of Neurology — Zengcheng District People′s Hospital of Guangzhou, avec 2 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Antiplatelet Therapy and Cardiovascular DiseasesHealth Systems, Economic Evaluations, Quality of LifeVenous Thromboembolism Diagnosis and Management

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.